Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892869 | 0.93 | CHEK1 (0.62) | CHEK1CDK1KDR | |
| SCHEMBL4931239 | 0.88 | MAPK3 (0.54) | CHEK1PAK4CDK2FLT3 | |
| SCHEMBL5188932 | 0.88 | PDE4A (0.50) | PAK4CDK2FLT3 | |
| SCHEMBL4893662 | 0.86 | FLT3 (0.52) | PAK4CDK2FLT3 | |
| SCHEMBL4884451 | 0.82 | CHEK1 (0.49) | CHEK1PDPK1CDK1PAK4CDK2 | |
| SCHEMBL5192052 | 0.81 | AURKA (0.55) | CHEK1PDPK1CDK1PAK4CDK2 | |
| SCHEMBL4896307 | 0.81 | CHEK1 (0.52) | CHEK1CDK1KDRFLT3 | |
| SCHEMBL5189495 | 0.80 | AURKA (0.49) | CHEK1CDK1CDK2KDR | |
| SCHEMBL5188939 | 0.79 | CHEK1 (0.48) | CHEK1CDK1CDK2FLT3 | |
| SCHEMBL4915031 | 0.79 | CHEK1 (0.70) | CHEK1PDPK1CDK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2008524151-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1831224-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | claimed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | claimed |
| WO-2006063841-A2 | TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| US-20060142247-A1 | Tricyclic heterocycles | HOFFMANN-LA ROCHE INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142247-A1 | Tricyclic heterocycles | CYP11B1, CYP11B2, CYP3A43 | CHEK1 531/4885PDPK1 2511/4885CDK1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.